Welcome

Welcome to the Theravet investors website,

Here you will find all the financial information dedicated to shareholders and investors

03/07/2025 - 19:51

DECISION OF THE BOARD OF DIRECTORS TO FILE FOR BANKRUPTCY

01/28/2025 - 16:00

DECISION BY EURONEXT TO CLASSIFY THE ASSET CONTRIBUTION OF THE H4 ORPHAN PHARMA LICENSE TO THERAVET AS A REVERSE TAKEOVER

11/18/2024 - 18:08

EGEIRO's Board of Directors acknowledges the resignation of Enrico Bastianelli and modifies its governance

10/29/2024 - 07:50

TheraVet becomes EGEIRO Pharma Minutes of the TheraVet EGM of October 28, 2024

09/30/2024 - 07:30

TheraVet announces a strategic transformation project aimed at creating a leader in human idiopathic pulmonary fibrosis

09/12/2024 - 07:35

2024 half-year results

All press releases

THERAVET

This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.

NewCap

Investors Relations

Théo Martin
+33 (0)1 44 71 94 94

Media Relations

Arthur Rouillé
+33 (0)1 44 71 00 15

Suscribe to the Newsletter Ask us your questions